| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/24/2013 | CA2841954A1 Treatment for hypoxia |
| 01/24/2013 | CA2841906A1 Azabenzimidazole derivative having ampk-activating activity |
| 01/24/2013 | CA2841899A1 Btk inhibitors |
| 01/24/2013 | CA2841887A1 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors |
| 01/24/2013 | CA2841886A1 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
| 01/24/2013 | CA2841851A1 Composition and method for treating hpv |
| 01/24/2013 | CA2841757A1 Gpr 119 modulators |
| 01/24/2013 | CA2841751A1 Method for timing a colonoscopy wherein a picosulate composition is administered |
| 01/24/2013 | CA2841748A1 Compositions and methods for modulating metabolic pathways |
| 01/24/2013 | CA2841724A1 Heart failure suppressing agent |
| 01/24/2013 | CA2841645A1 Azetidine derivatives for treatment of melanin related disorders |
| 01/24/2013 | CA2841629A1 Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| 01/24/2013 | CA2841552A1 Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| 01/24/2013 | CA2841546A1 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors |
| 01/24/2013 | CA2841449A1 Platinum(iv) complexes and pharmaceutical composition containing the same |
| 01/24/2013 | CA2841367A1 Oral compositions comprising an antacid, an anaesthetic and an inorganic matrix comprising silicon dioxide and titanium dioxide |
| 01/24/2013 | CA2841358A1 Pharmaceutical compositions for rectal administration |
| 01/24/2013 | CA2841102A1 Novel substituted indole derivatives as gamma secretase modulators |
| 01/24/2013 | CA2841003A1 Permanent attachment of pigments and dyes to surfaces containing calkyl-oh functionality |
| 01/24/2013 | CA2838793A1 Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
| 01/24/2013 | CA2837275A1 Boiled sugar sweet comprising non-fructosylated a-galactooligosaccharides |
| 01/24/2013 | CA2834199A1 Benzamides |
| 01/23/2013 | EP2548880A2 Compositions for increasing telomerase activity |
| 01/23/2013 | EP2548879A1 Crystal of diamine derivative and method of producing same |
| 01/23/2013 | EP2548878A1 Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands |
| 01/23/2013 | EP2548877A1 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| 01/23/2013 | EP2548876A1 New CRTh2 antagonists |
| 01/23/2013 | EP2548874A2 Substituted piperazines as CB1 antagonists |
| 01/23/2013 | EP2548873A1 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors |
| 01/23/2013 | EP2548872A1 Cyclopropanecarboxylic acid derivative |
| 01/23/2013 | EP2548871A1 Cycloalkyl-substituted imidazole derivative |
| 01/23/2013 | EP2548870A1 Process for the Synthesis of Cyclic Alkylene Ureas |
| 01/23/2013 | EP2548869A1 Process for the Synthesis of N-substituted Cyclic Alkylene Ureas |
| 01/23/2013 | EP2548868A1 Method and process for preparation and production of deuterated -diphenylurea |
| 01/23/2013 | EP2548867A1 Method for preparing deuterated diphenylurea |
| 01/23/2013 | EP2548866A1 New biologically active compound n-[3-(4-nitrophenylamino)-indol-2-ylmethylene]aminoguanidine hydrochloride with anti-inflammatory activity |
| 01/23/2013 | EP2548865A1 Novel bis-indolic derivatives, their uses in particular as antibacterials |
| 01/23/2013 | EP2548864A1 Novel bis-indolic derivatives, a process for preparing the same and their uses as a drug |
| 01/23/2013 | EP2548863A1 New CRTh2 antagonists. |
| 01/23/2013 | EP2548618A2 Organic compounds |
| 01/23/2013 | EP2548581A2 A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| 01/23/2013 | EP2548570A1 Pharmaceutical composition for treating a metabolic syndrome |
| 01/23/2013 | EP2548561A1 Semuloparin for improving the survival of patients with locally advanced cancer |
| 01/23/2013 | EP2548560A1 Compositions and methods for modulation of SMN2 splicing |
| 01/23/2013 | EP2548559A1 Methods and compositions for treating gastrointestinal disorders |
| 01/23/2013 | EP2548558A1 Nitrogen-containing condensed heterocyclic as inhibitors of bruton's tyrosine kinase |
| 01/23/2013 | EP2548557A1 Reserpine to treat cognitive faults of the central nervous system |
| 01/23/2013 | EP2548556A1 Method for improving dissolvability of anticoagulant |
| 01/23/2013 | EP2548555A1 Proton pump inhibitors as immunomodulators |
| 01/23/2013 | EP2548554A1 Inhibitor of in vivo proteolysis |
| 01/23/2013 | EP2548553A1 Galenical formulations of aliskiren |
| 01/23/2013 | EP2548552A2 Titration package for 1-amino-alkylcylohexanes |
| 01/23/2013 | EP2548456A1 Emulsions including a PEG-derivative of tocopherol |
| 01/23/2013 | EP2548453A1 High-potency sweetener for hydration and sweetened hydration composition |
| 01/23/2013 | EP2548441A1 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
| 01/23/2013 | EP2547768A1 Modified u7 snrnas for treatment of neuromuscular diseases |
| 01/23/2013 | EP2547715A2 Cleavable modifications to reducible poly (amido ethylenimines)s to enhance nucleotide delivery |
| 01/23/2013 | EP2547696A2 Fragments of the pa subunit of rna dependent rna polymerase from pandemic influenza virus a 2009 h1n1, and their use |
| 01/23/2013 | EP2547686A1 Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as beta - secretase modulators and their medical use |
| 01/23/2013 | EP2547685A1 Spiro-tetracyclic ring compounds as beta - secretase modulators |
| 01/23/2013 | EP2547684A1 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| 01/23/2013 | EP2547682A1 Solid state forms of sitagliptin salts |
| 01/23/2013 | EP2547681A1 Tosylate salt of cyclopropanecarboxylic acid 4-(6-chloro-3 -methyl-4,10-dihydro-3h-2,3,4,9-tetrabenzo[f]azulene-9-carbonyl)-2-fluorobenzylamide |
| 01/23/2013 | EP2547680A1 Imidazopyrazines |
| 01/23/2013 | EP2547679A1 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
| 01/23/2013 | EP2547678A1 Anti-infective compounds |
| 01/23/2013 | EP2547676A2 Modulators of hec1 activity and methods therefor |
| 01/23/2013 | EP2547674A1 Process for the preparation of malic acid salt of sunitinib |
| 01/23/2013 | EP2547673A1 A substituted pyrimidine as a prostaglandin d2 receptor antagonist |
| 01/23/2013 | EP2547672A1 Substituted pyrimidines as prostaglandin d2 receptor antagonists |
| 01/23/2013 | EP2547668A1 Toluidine blue derivatives as photosensitising compounds |
| 01/23/2013 | EP2547664A1 Morpholinylquinazolines |
| 01/23/2013 | EP2547662A1 Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists |
| 01/23/2013 | EP2547661A2 Indazole compounds and their uses |
| 01/23/2013 | EP2547660A1 Nitroxyl (hno) releasing compounds and uses thereof in treating diseases |
| 01/23/2013 | EP2547658A1 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 01/23/2013 | EP2547656A1 Pyridine and pyrazine derivative for the treatment of cf |
| 01/23/2013 | EP2547655A2 Arylsulfonamide ccr3 antagonists |
| 01/23/2013 | EP2547650A1 Agomelatine hydrobromide hydrate and preparation thereof |
| 01/23/2013 | EP2547649A1 Agomelatine hydrochloride hydrate and preparation thereof |
| 01/23/2013 | EP2547401A1 Inhibitors of glycogen synthase kinase 3 for use in therapeutic methods and screening method relating thereto |
| 01/23/2013 | EP2547366A2 Myeloid derived suppressor cell inhibiting agents |
| 01/23/2013 | EP2547349A1 Cancer therapy with a parvovirus combined with an hdac inhibitor |
| 01/23/2013 | EP2547345A1 Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides |
| 01/23/2013 | EP2547344A1 Esterified polysaccharide osmotic agents |
| 01/23/2013 | EP2547343A2 Use of p2x purinergic receptor agonists to enhance insulin secretion in pancreatic beta cells |
| 01/23/2013 | EP2547342A2 Combined use of phospholipid and sulfate groups-carrying polysaccharides for inhibiting metastatic spread |
| 01/23/2013 | EP2547341A1 Treatment for pulmonary hypertension |
| 01/23/2013 | EP2547340A2 Ophthalmic formulations of cetirizine and methods of use |
| 01/23/2013 | EP2547339A1 Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| 01/23/2013 | EP2547338A2 Imidazopyridine compounds, compositions and methods of use |
| 01/23/2013 | EP2547337A1 Use of anticoagulants in the production of recombinant proteins in the milk of transgenic animals |
| 01/23/2013 | EP2547336A1 A natural substance based antioxidant and chemoprotective agent and its method of production |
| 01/23/2013 | EP2547335A2 Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport |
| 01/23/2013 | EP2547334A1 Novel compounds and compositions for targeting cancer stem cells |
| 01/23/2013 | EP2547333A2 Stable bortezomib formulations |
| 01/23/2013 | EP2547330A2 Orally disintegrating tablet formulations of donepezil and process for preparing the same |
| 01/23/2013 | EP2547323A2 Pharmaceutical composition for treatment of increased intraocular pressure |
| 01/23/2013 | EP2547322A2 Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns |
| 01/23/2013 | EP2547217A1 Infant nutrition for improving fatty acid composition of brain membranes |